An Open-Label, Single-Dose, Study to Assess the Metabolism and Elimination of Varespladib After Oral Administration of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects.

Trial Profile

An Open-Label, Single-Dose, Study to Assess the Metabolism and Elimination of Varespladib After Oral Administration of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2011

At a glance

  • Drugs Varespladib (Primary)
  • Indications Acute coronary syndromes; Atherosclerosis; Coronary artery disease; Myocardial infarction
  • Focus Pharmacokinetics
  • Most Recent Events

    • 18 Oct 2011 Actual end date (July 2011) added as reported by ClinicalTrials.gov.
    • 18 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jun 2011 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top